About
BB
Ended--
Last price (USDT)
55.28K
24h total (USDT)
448.93K
Total vol (USDT)
2024-04-25 08:00:00 ~ 2024-05-13 09:30:00
Trading time (UTC+0)
2024-05-13 12:00:00
Delivery time (UTC+0)
Total supply2.10B
Resources
Introduction
BounceBit is the first-ever native BTC Restaking chain. The BounceBit network is secured by staking both Bitcoin and BounceBit tokens. BounceBit's PoS mechanism introduces a unique dual-token staking system by leveraging native BTC security with full EVM compatibility.
Exchange Traded Funds Top 10 Percentage Gainers
NET % STOCK (Symbol) LAST CHG CHG Leverage 2X Lg OKTA Dly OKTG 40.83 14.81 56.94 Leverage 2X Lg CRM Dly CRMG 9.68 2.97 44.26 GrShr 2x Long CRWD Daily CRWL 82.04 23.37 39.83 ProSh Ultra Solana ETF SLON 37.56 7.90 26.64 2x Solana ETF SOLT 67.71 14.11 26.32 Direxion PANW Bull 2X PALU 61.16 12.42 25.48 Leverage 2x Lg FIG Dly FIGG 34.00 6.87 25.34 Leverage 2X Lg PANW Dly PANG 37.48 7.55 25.22 Defiance Dly Tgt 2x Lg MSTX 16.24 3.03 22.94 GrShr 2x Long BB Daily BBUL 13.23 2.37 21.81 (END) Dow Jones Newswires August 27, 2026 17:38 ET (21:38 GMT)
Canadian Stocks Climb 0.1%
This article was automatically generated by Dow Jones using technology from Automated Insights. Stocks in Canada rose Thursday, as the S&P/TSX Composite Index gained 0.1% to 36834.25. Among large local companies, BlackBerry was the biggest leader during the session, surging 11%, and Obsidian Energy jumped 6.6%. Osisko Metals rounded out the top three movers, as shares jumped 6.5%. EQB was the biggest laggard, plunging 6.6%, followed by shares of Cronos Group, which tumbled 5.1%. Shares of Groupe Dynamite dropped 3.6%. Stock indexes in the U.S. rose as the Nasdaq Composite Index increased 1.6%. Meanwhile, the S&P 500 Index gained 0.7%, and the Dow Jones Industrial Average gained 0.2%. On the currency front, the WSJ Dollar Index held steady at 95.53. The Canadian dollar strengthened 0.2% against the U.S. dollar to US$0.72. In the bond markets, the 10-year Canadian government bond yield increased 4.78 basis points to 3.702%. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires August 27, 2026 16:31 ET (20:31 GMT)
BlackBerry Adds Hailo-8 AI Accelerator Support to QNX
03:23 PM EDT, 08/27/2026 (MT Newswires) -- BlackBerry's (BB) QNX division said Thursday it added support for the Hailo-8 AI accelerator to its software development platform, expanding hardware options for edge computing systems. The technological pairing targets mission-critical deployments across the automotive, robotics and industrial sectors that demand deterministic, real-time operational reliability. Hardware benchmarking assessments demonstrated that the combined system delivered increased data throughput, reduced latency and improved processing consistency compared with a real-time Linux environment. Shares of BlackBerry were up more than 9% in Thursday trading. Price: 8.52, Change: +0.73, Percent Change: +9.31
Canadian Stocks Decrease 0.3% In Morning Trading
This article was automatically generated by Dow Jones using technology from Automated Insights. Stocks in Canada slipped during early trading Thursday, as the S&P/TSX Composite Index fell 0.3% to 36696.75. Among local companies with a market cap of at least 1 billion Canadian dollars ($721.5 million), EQB is the biggest early laggard, tumbling 9.3%, followed by shares of Canadian Imperial Bank, which declined 2.8%. Shares of G Mining Ventures dropped 2.7%. BlackBerry is the biggest leader this morning, jumping 5.6%, and Aya Gold & Silver surged 5.2%. Hut 8 rounds out the top three movers, as shares gained 4.7%. On the currency front, the WSJ Dollar Index held steady at 95.51. The Canadian dollar strengthened 0.1% against the U.S. dollar to US$0.72. In the bond markets, the 10-year Canadian government bond yield increased 1.64 basis points to 3.670%. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires August 27, 2026 10:11 ET (14:11 GMT)
Sector Update: Tech Stocks Advance Premarket Tuesday
09:10 AM EDT, 08/25/2026 (MT Newswires) -- Technology stocks were advancing premarket Tuesday, with the State Street Technology Select Sector SPDR Fund (XLK) up 1.1% and the State Street SPDR S&P Semiconductor ETF (XSD) 2.5% higher. Cisco Systems (CSCO) shares were up more than 1% after the company launched its Sovereign Critical Infrastructure portfolio in Canada for government agencies and organizations operating critical infrastructure. CoreWeave (CRWV) said Rescale will expand its cloud ecosystem to CoreWeave Cloud to support artificial intelligence and simulation workloads for product development. CoreWeave stock was up more than 2% pre-bell. BlackBerry (BB) Chief Executive John Giamatteo told CNBC that Robotics is one of the fastest-growing businesses within its QNX software division. Shares of BlackBerry were up more than 1% premarket.
Market Chatter: BlackBerry Sees Robotics as Key Growth Area
06:25 AM EDT, 08/25/2026 (MT Newswires) -- BlackBerry (BB) Chief Executive John Giamatteo told CNBC on Tuesday that Robotics is one of the fastest-growing businesses within its QNX software division. QNX, which provides safety-critical software for vehicles, is now also being used in industrial robots, robotic forklifts and medical equipment, said Giamatteo, who sees these areas as a major opportunity as physical artificial intelligence develops, CNBC reported. BlackBerry has a $950 million QNX order backlog, with some orders tied to robotics, CNBC said, adding that the company did not disclose the exact amount. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
YZi Labs-Backed BounceBit to Shut Down L1 After 286.5M BB Exploit
YZi Labs-backed BounceBit will shut down its Layer 1 blockchain after an attacker drained 286.5 million BB tokens from nine accounts in an exploit that exposed a flaw in the network’s authorization system. The attack took place between Aug. 19 and 20 and did not involve the theft of private keys, according to the project. Instead, the attacker exploited a weakness in how transactions were authorized on BounceBit Chain. The network halted block production after the unauthorized transfers. BounceBit will reissue BB as a BEP-20 token on BNB Chain, using a snapshot of balances recorded at block 20,697,260 before the attack. The stolen tokens will not be included in the new supply. Holders do not need to take any action during the reissuance, according to BounceBit. Staked and unbonding balances will also receive credits based on the snapshot. The attacker used primary accounts and 15 single-use contracts to exploit the flaw, allowing unauthorized accounts to become funding sources. BounceBit said the incident did not compromise wallets, private keys, signatures, hardware devices or exchange accounts. The project will coordinate with exchanges on affected deposits and has warned holders to avoid unofficial migration links or newly issued BB contracts. The shutdown will end BounceBit’s standalone blockchain as the project shifts its products to BNB Chain. div#ce-iframe-ads div#frame { margin: auto; text-align: center; }
Pump.fun Sells Another $12.5M in SOL as Solana Rally Continues
Pump.fun, the Solana-based token launchpad, has sold an additional 143,500 SOL, worth approximately $12.52 million, according to blockchain analytics firm Lookonchain. The sale comes as Solana’s native token continues its upward momentum, with the platform’s cumulative SOL sales now reaching 4.9779 million tokens, valued at roughly $820 million at an average price of $164.8 per SOL. Ongoing SOL Sales and Market Impact Lookonchain’s on-chain data reveals that Pump.fun has been steadily offloading its SOL holdings over recent months. This latest transaction is part of a broader pattern where the platform periodically sells SOL to manage treasury operations or convert proceeds into stablecoins. The average sale price of $164.8 indicates that Pump.fun has been selling into strength, capitalizing on Solana’s price appreciation. Solana has been one of the best-performing major cryptocurrencies this year, driven by increased network activity, a surge in meme coin launches, and growing institutional interest. The token’s rally has been supported by a robust ecosystem of decentralized applications, including Pump.fun, which has facilitated the creation of thousands of tokens. Context and Implications for Solana’s Ecosystem While large sales by prominent entities can sometimes raise concerns about market pressure, Pump.fun’s actions appear to be part of a routine treasury management strategy rather than a signal of bearish sentiment. The platform has consistently sold SOL in tranches, and the market has absorbed these sales without significant disruption. For traders and investors, monitoring such on-chain movements is crucial for understanding potential liquidity dynamics. However, the overall trend in Solana’s price remains influenced by broader market factors, including Bitcoin’s performance, regulatory developments, and network fundamentals. Why This Matters Pump.fun’s sales are notable because they reflect the revenue generation of a major Solana-based platform. As one of the most active token launchpads, Pump.fun’s financial activities can serve as a barometer for the health of the Solana ecosystem. The platform’s ability to sell large amounts of SOL at favorable prices underscores the economic vitality of the network and its capacity to generate real revenue from user activity. Conclusion Pump.fun’s latest SOL sale of $12.5 million is a routine but significant event, highlighting the ongoing monetization of Solana’s ecosystem. As the token’s price continues to rally, such sales are likely to persist, providing a steady stream of liquidity to the platform while reinforcing Solana’s position as a leading blockchain for token launches. FAQs Q1: What is Pump.fun? Pump.fun is a decentralized token launchpad on the Solana blockchain that allows users to create and trade meme coins and other tokens easily. It has become one of the most popular platforms for token launches in the Solana ecosystem. Q2: Why is Pump.fun selling SOL? Pump.fun sells SOL to manage its treasury, convert earnings into stablecoins, or fund operations. The platform has sold SOL periodically, and the recent sale is part of its routine financial management strategy. Q3: How does Pump.fun’s SOL sale affect Solana’s price? While large sales can temporarily increase selling pressure, the impact is often limited if the market has sufficient liquidity. In this case, Solana’s price has continued to rally, indicating that the market is absorbing the sales without significant negative effects.
Estonian Financial Regulator Issues Investor Warning to Zondacrypto Due to Absence of White Paper
ChainCatcher news, according to Cointelegraph, the Estonian financial regulator has issued an investor warning to BB Trade Estonia OÜ, operator of the crypto exchange Zondacrypto, for failing to provide the whitepaper for the “TeamPL” crypto token on its website. This violates Article 9, Section 1 of the EU MiCA framework, which requires the whitepaper to remain publicly available on the website as long as the crypto asset is held by the public.
BB (BounceBit) fluctuated 40.6% in 24 hours: price rebounded from a low of $0.0249 to a high of $0.035, driven by surging buy volume
Volatility Brief In the past 24 hours, BB’s price hit a low of $0.0249 and a high of $0.035, with the current price at $0.0343, reflecting an overall price swing of 40.6%. The 24-hour trading volume ranged from approximately $4.5 million to $7.5 million, down about 50% from the previous day, indicating that volatility is accompanied by tightening liquidity. Reasons for Unusual Movement - Buy volume surged abnormally by 15.2 times, pushing the price to rebound from the $0.0252 support area, with short-term momentum turning bullish. - There has been no official announcement or significant news event in the past 24 hours; there are no notable reports of on-chain whale activity or significant net fund inflows, indicating the volatility mainly stems from technical support accumulation and trader entries. Market Opinion and Outlook The overall sentiment among the community and traders is cautiously optimistic. If the price holds above the $0.0250–0.0254 support, a test of the $0.0260–0.0270 resistance is expected; however, a drop below $0.0248 would turn the trend bearish, targeting $0.0243. Analysts emphasize the need to confirm the rebound pattern and to avoid the risks associated with liquidity grabbing. Note: This analysis is automatically generated by AI based on public data and on-chain monitoring. For reference purposes only.
BB
Finally some good movement . BUT real bullishness only starts from breaking the 8$ and the dotted yellow line i have drawn . This is a multi year falling wedge . Breaking this .. sky is the limit .
After a brief trading halt, Bed Bath & Beyond (BBBY) resumed pre-market trading and its stock price jumped by 9.2%.
The company simultaneously announced the acquisition of Lumber Liquidators, Cabinets to Go, and other F9 brand assets, a strategic move that has significantly boosted market confidence. This acquisition marks Bed Bath & Beyond's strategic expansion into the home renovation segment. By integrating Lumber Liquidators' expertise in flooring retail with Cabinets to Go's custom kitchen cabinet solutions, BBBY is expected to build a more comprehensive home living ecosystem. The addition of the F9 brand asset bundle will further strengthen the synergy within its product portfolio. Capital markets responded positively, with pre-market gains surpassing 9%, highlighting investors' recognition of the merger and acquisition strategy. Analysts pointed out that this deal will not only rapidly expand BBBY's revenue base but, more importantly, break through growth bottlenecks through category complementation. As demand for home consumption continues to rise, the integrated multi-brand strategy may become a new engine driving performance.
Banco do Brasil Launches Pix in Argentina and Prepares Expansion to Other Countries
Banco do Brasil announced the launch of a payment function via instant transfer system Pix for Brazilian citizens staying in Argentina. The new service allows users to pay in Argentine stores directly through a banking app with automatic currency conversion. Banco do Brasil (BB), together with Argentina’s Banco Patagonia, launched cross-border payments via Pix, which previously operated only within Brazil’s domestic market. Now any Pix user, regardless of whether they’re a Banco do Brasil client, can pay for purchases in Argentina by scanning QR codes at participating retail locations. This was reported by Reuters. The new function allows Brazilians in Argentina to pay for goods in real time. The buyer sees the charge in Brazilian reais, while the merchant receives funds in Argentine pesos. Currency conversion and tax calculations are handled by BB, while the final amount is shown to the customer before confirming the transaction. Sistema de Pagamentos Instantâneos (SPI), the national instant payment system better known as Pix, was created by Banco do Brasil. It operates 24/7 and is free for individuals. Around 900 financial institutions are connected to the system, and the number of users exceeds 170 million people. It’s the most popular cashless payment method in the country. According to Felipe Prince , VP for Internal Controls and Risk Management at BB, launching Pix abroad strengthens the international direction of Banco do Brasil’s business and is part of its global strategy. Argentina became the first stage of this expansion. In the future, the bank is considering implementing the service in other countries in the Americas, as well as in Europe and Asia, primarily where large Brazilian diasporas live. The expansion of Pix into the Argentine market comes amid the active digitalization of the country’s financial sector and growing use of cryptocurrency infrastructure. According to a Lemon report, in 2025, Argentina ranked second in Latin America by the volume of received crypto transactions, which exceeded $93.9 billion, with annual growth of around 3%. At the same time, the country leads the region in the number of active users of crypto applications per capita — 12% of the population uses cryptocurrencies, accounting for more than a quarter of all activity in Latin America. A particularly notable example is the integration of Argentine FinTech companies with Brazil’s Pix system. According to the report, in 2025, Argentina recorded 5.4 million downloads of crypto apps, with more than 90% of them belonging to wallets that implemented Pix-based payments in Brazil. The peak in downloads occurred in January 2025 and exceeded the previous maximum by over 80%. Thus, the launch of Pix in Argentina by Banco do Brasil fits into a broader trend — the integration of instant payment systems and alternative payment tools into the region’s everyday economy. For millions of Brazilians who regularly visit Argentina, the new feature removes the need for currency exchange, international cards, or opening local accounts, enabling direct payments through the familiar Pix infrastructure, which in 2025 also integrated cryptocurrency payment solutions such as Binance Pay and KuCoin Pay.
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low dose BB-301 experienced highly durable improvements, with clinical and radiographic improvements continuing to deepen two years post BB-301 treatment -The first OPMD Patient treated with high dose BB-301 experienced an extraordinarily robust dose-response at an early interim follow-up time-point, indicating the continued potential for BB-301 to achieve disease-modifying outcomes for OPMD patients with dysphagia - BB-301 is the only clinical-stage therapeutic in development designed to treat dysphagia in patients with OPMD HAYWARD, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced promising interim clinical results from the BB-301 Phase 1b/2a first-in-human study (NCT06185673) evaluating low dose and high dose BB-301 treatment for Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagia. Interim and long-term clinical results for patients enrolled into Cohort 1 (low dose BB-301 ), and interim clinical results for the first patient enrolled into Cohort 2 (high dose BB-301) in the ongoing clinical trial will be presented as a late-breaking poster presentation at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, in Orlando, Florida on March 9, 2026. “We are strongly encouraged by the 100% response rate and the depth and durability of the responses that have been observed for all patients treated with BB-301 to date,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “We are incredibly excited to share these interim clinical results which demonstrate positive, clinically meaningful improvements across the most critical radiographic, functional, and patient-reported assessments of swallowing function. With no currently approved treatments for OPMD patients, the results presented today represent an important step towards the management of the unmet medical need that exists in the OPMD community. We remain committed to advancing the BB-301 program, and we are deeply grateful to the patients, their families, and our investigators whose unyielding commitment continues to make this progress possible.” BB-301 Phase 1b/2a Clinical Treatment Study Background: The BB-301 Phase 1b/2a clinical study (NCT06185673) is an open-label, dose escalation study evaluating the safety and clinical activity of intramuscular doses of BB-301 to treat moderate dysphagia in patients with OPMD. The following parameters represent the core assessments of BB-301 efficacy for each study participant: Sydney Swallow Questionnaire (SSQ), pharyngeal area at maximum constriction (PhAMPC), total pharyngeal residue (TPR) and normalized residue ratio scale-valleculae (NRRS v ). The SSQ is a validated 17-item patient-reported outcome instrument that assesses the total dysphagic symptom burden experienced by a patient. The PhAMPC is assessed by videofluoroscopic swallowing studies (VFSS) and serves as a surrogate for the functional capacity of the pharyngeal constrictor muscles during the swallowing cycle. The TPR is assessed by VFSS and represents the quantity of food and liquid material (residue) remaining in the throat upon completion of a swallow (post-swallow residue). The NRRS v is assessed by VFSS and represents the quantity of food and liquid material (residue) remaining in the vallecular region of the throat upon completion of a swallow (post-swallow residue). Key interim clinical study results to be presented at the 2026 MDA Clinical & Scientific Conference include: Interim Clinical Results for High Dose BB-301 (Cohort 2): High dose BB-301 is being evaluated for the potential to facilitate more rapid clinical improvements and/or greater magnitudes of clinical improvements across the core functional, anatomical, and symptom-focused elements of the dysphagic symptom burden experienced by OPMD patients Patient B (Cohort 2, high dose BB-301) safely received the high dose of BB-301 with no treatment-related SAEs Patient B (Cohort 2, high dose BB-301) and Patient A (Cohort 1, low dose BB-301) had comparable baseline functional, anatomical, and symptom-focused deficits prior to the administration of BB-301 When comparing 3-month post-BB-301-treatment clinical results for Patient A and Patient B, Patient B experienced a significant improvement in depth of response to high dose BB-301 Patient B, the first OPMD Patient treated with high dose BB-301, experienced an extraordinarily robust dose-response at an early interim follow-up time-point, indicating the continued potential for BB-301 to achieve disease-modifying outcomes for OPMD patients with dysphagia. When comparing the interim clinical results for the low dose BB-301 treatment and the high dose BB-301 treatment at the 3-month post-treatment time-point in Patients with comparable pre-treatment baseline deficits, the high dose BB-301 treatment demonstrated significantly improved results across all radiographic and patient-reported assessments employed in the BB-301 Phase 1b/2a Clinical Treatment Study: Significantly differentiated levels of dysphagic symptom burden reduction were observed, with a ~7% reduction in total dysphagic symptom burden (SSQ) achieved with low dose BB-301 as compared to a ~68% reduction in SSQ achieved with high dose BB-301 Significantly differentiated levels of throat closure were observed, with an ~8% improvement in throat closure (PhAMPC) achieved with low dose BB-301 as compared to a ~19% improvement in PhAMPC achieved with high dose BB-301 Significantly differentiated levels of overall throat emptying were observed, with a ~6% worsening in overall throat emptying (TPR) observed with low dose BB-301 as compared to a ~44% improvement in TPR achieved with high dose BB-301 Significantly differentiated levels of throat emptying from the vallecular region were observed, with a ~3% improvement in throat emptying from the vallecular region (NRRS v ) achieved with low dose BB-301 as compared to a ~57% improvement in NRRS v with high dose BB-301 Interim Clinical Results for Low Dose BB-301 (Cohort 1): All Study Completers in Cohort 1 (low dose BB-301) are formal Responders to BB-301 Completers are Patients that have reached the 12-month post-BB-301-treatment assessment time-point in the BB-301 Phase 1b/2a Clinical Treatment Study Long-term efficacy trends for low dose BB-301 at 24-months post BB-301 treatment continue to demonstrate robust disease-modifying outcomes for throat closure, throat emptying, and total dysphagic symptom burden Late-Breaking Poster Presentation An interim clinical study update for the Phase 1b/2a Clinical Treatment Study of BB-301 in OPMD subjects with moderate dysphagia will be provided in a late-breaking poster presentation, (poster number 501 LB) entitled “Durable Responses to Low Dose BB-301 in Oculopharyngeal Muscular Dystrophy at 12- and 24-months and Improved Depth of Response to High Dose BB-301” during poster sessions from 10:15-10:45 am, 12:00-1:30 pm, 3:30-4:00 pm and 6:00-8:00 pm Eastern Time on March 9 th in the Exhibit Hall at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. The poster is available on the Benitec website. About OPMD There are currently no approved therapies for OPMD, a rare autosomal-dominant degenerative muscle disorder, that impacts nearly 15,000 patients in North America, Europe and Isreal. OPMD is caused by a mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene; PABPN1 is a ubiquitous protein that controls the length of mRNA poly(A) tails, mRNA export from the nucleus and alternative poly(A) site usage. OPMD is a debilitating progressive disease that weakens the pharyngeal muscles, causing severe swallowing difficulties (dysphagia). 1 Progressive dysphagia impacts 97% of OPMD patients and is a severe, life-threatening complication of OPMD which can lead to chronic choking, malnutrition, aspiration pneumonia and death. About BB-301 BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by halting mutant PABPN1 expression while providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA. About Benitec Biopharma Inc. Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). Forward Looking Statements Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of pre-clinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel AAV vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities and other regulatory developments; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; the impact of, and our ability to remediate, the identified material weakness in our internal controls over financial reporting; the impact of local, regional, and national and international economic conditions and events; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low dose BB-301 experienced highly durable improvements, with clinical and radiographic improvements continuing to deepen two years post BB-301 treatment -The first OPMD Patient treated with high dose BB-301 experienced an extraordinarily robust dose-response at an early interim follow-up time-point, indicating the continued potential for BB-301 to achieve disease-modifying outcomes for OPMD patients with dysphagia - BB-301 is the only clinical-stage therapeutic in development designed to treat dysphagia in patients with OPMD HAYWARD, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced promising interim clinical results from the BB-301 Phase 1b/2a first-in-human study (NCT06185673) evaluating low dose and high dose BB-301 treatment for Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagia. Interim and long-term clinical results for patients enrolled into Cohort 1 (low dose BB-301 ), and interim clinical results for the first patient enrolled into Cohort 2 (high dose BB-301) in the ongoing clinical trial will be presented as a late-breaking poster presentation at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, in Orlando, Florida on March 9, 2026. “We are strongly encouraged by the 100% response rate and the depth and durability of the responses that have been observed for all patients treated with BB-301 to date,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “We are incredibly excited to share these interim clinical results which demonstrate positive, clinically meaningful improvements across the most critical radiographic, functional, and patient-reported assessments of swallowing function. With no currently approved treatments for OPMD patients, the results presented today represent an important step towards the management of the unmet medical need that exists in the OPMD community. We remain committed to advancing the BB-301 program, and we are deeply grateful to the patients, their families, and our investigators whose unyielding commitment continues to make this progress possible.” BB-301 Phase 1b/2a Clinical Treatment Study Background: The BB-301 Phase 1b/2a clinical study (NCT06185673) is an open-label, dose escalation study evaluating the safety and clinical activity of intramuscular doses of BB-301 to treat moderate dysphagia in patients with OPMD. The following parameters represent the core assessments of BB-301 efficacy for each study participant: Sydney Swallow Questionnaire (SSQ), pharyngeal area at maximum constriction (PhAMPC), total pharyngeal residue (TPR) and normalized residue ratio scale-valleculae (NRRS v ). The SSQ is a validated 17-item patient-reported outcome instrument that assesses the total dysphagic symptom burden experienced by a patient. The PhAMPC is assessed by videofluoroscopic swallowing studies (VFSS) and serves as a surrogate for the functional capacity of the pharyngeal constrictor muscles during the swallowing cycle. The TPR is assessed by VFSS and represents the quantity of food and liquid material (residue) remaining in the throat upon completion of a swallow (post-swallow residue). The NRRS v is assessed by VFSS and represents the quantity of food and liquid material (residue) remaining in the vallecular region of the throat upon completion of a swallow (post-swallow residue). Key interim clinical study results to be presented at the 2026 MDA Clinical & Scientific Conference include: Interim Clinical Results for High Dose BB-301 (Cohort 2): High dose BB-301 is being evaluated for the potential to facilitate more rapid clinical improvements and/or greater magnitudes of clinical improvements across the core functional, anatomical, and symptom-focused elements of the dysphagic symptom burden experienced by OPMD patients Patient B (Cohort 2, high dose BB-301) safely received the high dose of BB-301 with no treatment-related SAEs Patient B (Cohort 2, high dose BB-301) and Patient A (Cohort 1, low dose BB-301) had comparable baseline functional, anatomical, and symptom-focused deficits prior to the administration of BB-301 When comparing 3-month post-BB-301-treatment clinical results for Patient A and Patient B, Patient B experienced a significant improvement in depth of response to high dose BB-301 Patient B, the first OPMD Patient treated with high dose BB-301, experienced an extraordinarily robust dose-response at an early interim follow-up time-point, indicating the continued potential for BB-301 to achieve disease-modifying outcomes for OPMD patients with dysphagia. When comparing the interim clinical results for the low dose BB-301 treatment and the high dose BB-301 treatment at the 3-month post-treatment time-point in Patients with comparable pre-treatment baseline deficits, the high dose BB-301 treatment demonstrated significantly improved results across all radiographic and patient-reported assessments employed in the BB-301 Phase 1b/2a Clinical Treatment Study: Significantly differentiated levels of dysphagic symptom burden reduction were observed, with a ~7% reduction in total dysphagic symptom burden (SSQ) achieved with low dose BB-301 as compared to a ~68% reduction in SSQ achieved with high dose BB-301 Significantly differentiated levels of throat closure were observed, with an ~8% improvement in throat closure (PhAMPC) achieved with low dose BB-301 as compared to a ~19% improvement in PhAMPC achieved with high dose BB-301 Significantly differentiated levels of overall throat emptying were observed, with a ~6% worsening in overall throat emptying (TPR) observed with low dose BB-301 as compared to a ~44% improvement in TPR achieved with high dose BB-301 Significantly differentiated levels of throat emptying from the vallecular region were observed, with a ~3% improvement in throat emptying from the vallecular region (NRRS v ) achieved with low dose BB-301 as compared to a ~57% improvement in NRRS v with high dose BB-301 Interim Clinical Results for Low Dose BB-301 (Cohort 1): All Study Completers in Cohort 1 (low dose BB-301) are formal Responders to BB-301 Completers are Patients that have reached the 12-month post-BB-301-treatment assessment time-point in the BB-301 Phase 1b/2a Clinical Treatment Study Long-term efficacy trends for low dose BB-301 at 24-months post BB-301 treatment continue to demonstrate robust disease-modifying outcomes for throat closure, throat emptying, and total dysphagic symptom burden Late-Breaking Poster Presentation An interim clinical study update for the Phase 1b/2a Clinical Treatment Study of BB-301 in OPMD subjects with moderate dysphagia will be provided in a late-breaking poster presentation, (poster number 501 LB) entitled “Durable Responses to Low Dose BB-301 in Oculopharyngeal Muscular Dystrophy at 12- and 24-months and Improved Depth of Response to High Dose BB-301” during poster sessions from 10:15-10:45 am, 12:00-1:30 pm, 3:30-4:00 pm and 6:00-8:00 pm Eastern Time on March 9 th in the Exhibit Hall at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. The poster is available on the Benitec website, and a link to the poster is found here. About OPMD There are currently no approved therapies for OPMD, a rare autosomal-dominant degenerative muscle disorder, that impacts nearly 15,000 patients in North America, Europe and Isreal. OPMD is caused by a mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene; PABPN1 is a ubiquitous protein that controls the length of mRNA poly(A) tails, mRNA export from the nucleus and alternative poly(A) site usage. OPMD is a debilitating progressive disease that weakens the pharyngeal muscles, causing severe swallowing difficulties (dysphagia). 1 Progressive dysphagia impacts 97% of OPMD patients and is a severe, life-threatening complication of OPMD which can lead to chronic choking, malnutrition, aspiration pneumonia and death. About BB-301 BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by halting mutant PABPN1 expression while providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA. About Benitec Biopharma Inc. Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com. Forward Looking Statements Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of pre-clinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel AAV vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities and other regulatory developments; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; the impact of, and our ability to remediate, the identified material weakness in our internal controls over financial reporting; the impact of local, regional, and national and international economic conditions and events; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements. References:
BlackBerry (BB) Outpaces Stock Market Gains: What You Should Know
BlackBerry (BB) ended the recent trading session at $3.48, demonstrating a +2.05% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.78% for the day. Meanwhile, the Dow experienced a rise of 0.49%, and the technology-dominated Nasdaq saw an increase of 1.29%. Shares of the cybersecurity software and services company have appreciated by 0.59% over the course of the past month, outperforming the Computer and Technology sector's loss of 3.59%, and the S&P 500's loss of 1.33%. The upcoming earnings release of BlackBerry will be of great interest to investors. The company is forecasted to report an EPS of $0.05, showcasing a 66.67% upward movement from the corresponding quarter of the prior year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.15 per share and a revenue of $538.01 million, signifying shifts of +650% and -6.22%, respectively, from the last year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for BlackBerry. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. BlackBerry is holding a Zacks Rank of #3 (Hold) right now. In terms of valuation, BlackBerry is currently trading at a Forward P/E ratio of 20.88. This represents a premium compared to its industry average Forward P/E of 19.88. The Internet - Software industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 141, putting it in the bottom 43% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
BlackBerry (BB) Registers a Bigger Fall Than the Market: Important Facts to Note
BlackBerry (BB) ended the recent trading session at $3.32, demonstrating a -3.77% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 1.04%. On the other hand, the Dow registered a loss of 1.66%, and the technology-centric Nasdaq decreased by 1.13%. Prior to today's trading, shares of the cybersecurity software and services company had lost 9.69% lagged the Computer and Technology sector's gain of 0.34% and the S&P 500's gain of 1.75%. The investment community will be paying close attention to the earnings performance of BlackBerry in its upcoming release. The company is expected to report EPS of $0.05, up 66.67% from the prior-year quarter. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.15 per share and a revenue of $538.01 million, representing changes of +650% and -6.22%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for BlackBerry. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. BlackBerry is currently a Zacks Rank #3 (Hold). Valuation is also important, so investors should note that BlackBerry has a Forward P/E ratio of 23.52 right now. This expresses a premium compared to the average Forward P/E of 18.99 of its industry. The Internet - Software industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 132, putting it in the bottom 47% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
-The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301- -Patient 1 of Cohort 1 completed the 24-month follow-up timepoint, and at the 24-month post-treatment timepoint Patient 1 continued to experience the disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint- - An update on the Interim clinical results for Cohort 2 is planned for mid-2026- -FDA meeting to formalize the pivotal BB-301 study design expected mid-year- HAYWARD, Calif.,, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission. “We continue to be encouraged by the benign safety profile and the durability of efficacy demonstrated in our BB-301 clinical development program,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “We look forward to engaging with the U.S. Food and Drug Administration (FDA) in mid-2026 to confirm the BB-301 pivotal study design and continuing to present interim clinical results at future medical conferences. I want to sincerely thank our investigators, our clinical advisors, and—most importantly—the patients and families who have made this progress possible.” The recent and upcoming key milestones related to the development of BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy-related Dysphagia, are outlined below: Responder Analysis for Study Completers A Responder Analysis was developed to facilitate standardized evaluation of BB-301 efficacy for each Patient. The Responder Analysis consists of multiple discrete response categories that collectively assess the dysphagic symptom burden in patients with OPMD. These response categories include: Patient-Reported Outcome: Patient-reported oral-pharyngeal dysphagia as assessed by the Sydney Swallow Questionnaire (SSQ) total score Videofluoroscopic Swallowing Study (VFSS) Assessments: Pharyngeal constrictor muscle function as estimated by the Pharyngeal Area at Maximum Constriction (PhAMPC) Swallowing efficiency as measured by NRRS v and Total Pharyngeal Residue %(C2-4) 2 Frequency of pathologic sequential swallows (SEQ) Functional Swallowing Capacity: Cold-Water Timed Drinking Test (CWDT) The evaluation is completed as follows: Following completion of the 12-month post-treatment follow-up timepoint, each discrete response category is evaluated for each study Completer using prespecified statistical criteria Results of the statistical characterization of each response category are combined into a single scoring framework that facilitates the overall assessment of clinical benefit achieved by each Completer following treatment with BB-301 A total Score of 5 is possible Responder status for each Completer will be assigned based on the achievement of statistical criteria for at least 2 out of 5 discrete response categories (≥40%) Responder Analysis for Study Completers: All four Cohort 1 Completers were formal responders to BB-301, demonstrating durable response to BB-301 at the conclusion of the 12-month statistical follow-up period. 24-Month Post-Treatment Follow-Up for Patient 1 of Cohort 1 At the 24-month post-BB-301 treatment follow-up timepoint, Patient 1 of Cohort 1 continued to demonstrate robust, disease-modifying outcomes. Patient 1 demonstrated deepening improvements in post-swallow pharyngeal residue as compared to the final pre-treatment timepoint and as compared to the 12-month post-treatment follow-up timepoint as assessed by VFSS. Patient 1 also experienced deepening improvements in total dysphagic symptom burden as assessed by the SSQ. Enrollment into the BB-301 Phase 1b/2a Clinical Treatment Study is Ongoing: The first Patient in Cohort 2 was safely treated with the higher-dose of BB-301 in 4Q of 2025 and an update on the interim clinical results of Cohort 2 is planned for mid-2026. Corporate Updates: The Company plans to engage with the FDA in mid-2026 to confirm the BB-301 pivotal study design. In November 2025, Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and the proprietary Responder Analysis planned for use in the BB-301 pivotal study. Previously, BB-301 has received Orphan Drug Designation from the EMA and the FDA. Financial Highlights Second Quarter 2026 Financial Results Total Expenses for the quarter ended December 31, 2025 were $13.4 million compared to $10.8 million for the quarter ended December 31, 2024. The Company incurred $5.8 million of research and development expenses which was in line with $5.4 million for the comparable quarter ended December 31, 2024. Research and development expenses relate primarily to ongoing clinical development of BB-301 for the treatment of OPMD. General and administrative expenses were $7.5 million compared to $5.4 million for the quarter ended December 31, 2024. The loss from operations for the quarter ended December 31, 2025, was $13.4 million compared to a loss of $10.8 million for the quarter ended December 31, 2024. Net loss attributable to shareholders for the quarter ended December 31, 2025, was $11.8 million, or $(0.26) per basic and diluted share, compared to a net loss of $9.6 million, or $(0.26) per basic and diluted share for the quarter ended December 31, 2024. As of December 31, 2025, the Company had $189 million in cash and cash equivalents, which includes $0.1 million from the exercise of warrants during the six-month period ended December 31, 2025. BENITEC BIOPHARMA INC. Consolidated Balance Sheets (in thousands, except par value and share amounts) December 31, 2025 June 30, 2025 (Unaudited) Assets Current assets: Cash and cash equivalents $ 188,790 $ 97,744 Restricted cash 113 113 Trade and other receivables 130 33 Prepaid and other assets 562 628 Total current assets 189,595 98,518 Property and equipment, net 115 131 Deposits 55 55 Prepaid and other assets 11 28 Right-of-use assets 905 860 Total assets $ 190,681 $ 99,592 Liabilities and stockholders’ equity Current liabilities: Trade and other payables $ 1,850 $ 1,022 Accrued employee benefits 483 426 Lease liabilities, current portion 468 354 Total current liabilities 2,801 1,802 Lease liabilities, less current portion 519 495 Total liabilities 3,320 2,297 Stockholders’ equity: Preferred stock, $0.0001 par value—5,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and June 30, 2025, respectively — — Common stock, $0.0001 par value—160,000,000 shares authorized; 34,254,907 and 26,250,469 shares issued and outstanding at December 31, 2025 and June 30, 2025, respectively 3 2 Additional paid-in capital 437,219 326,308 Accumulated deficit (248,978 ) (228,176 ) Accumulated other comprehensive loss (883 ) (839 ) Total stockholders’ equity 187,361 97,295 Total liabilities and stockholders’ equity $ 190,681 $ 99,592 BENITEC BIOPHARMA INC. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share amounts) Three Months Ended Six Months Ended December 31, December 31, 2025 2024 2025 2024 Revenue: $ — $ — $ — $ — Total revenues — — — — Operating expenses Research and development 5,834 5,385 9,204 8,970 General and administrative 7,543 5,420 13,976 7,626 Total operating expenses 13,377 10,805 23,180 16,596 Loss from operations (13,377 ) (10,805 ) (23,180 ) (16,596 ) Other income (loss): Foreign currency transaction gain (loss) 131 (294 ) 42 (201 ) Interest income, net 1,390 823 2,401 1,427 Other income (expense), net 19 (40 ) (65 ) (5 ) Gain on extinguishment of liabilities — 764 — 764 Total other income, net 1,540 1,253 2,378 1,985 Net loss $ (11,837 ) $ (9,552 ) $ (20,802 ) $ (14,611 ) Other comprehensive income: Unrealized foreign currency translation gain (loss) (133 ) 305 (44 ) 204 Total other comprehensive income (loss) (133 ) 305 (44 ) 204 Total comprehensive loss $ (11,970 ) $ (9,247 ) $ (20,846 ) $ (14,407 ) Net loss $ (11,837 ) $ (9,552 ) $ (20,802 ) $ (14,611 ) Net loss attributable to common shareholders $ (11,837 ) $ (9,552 ) $ (20,802 ) $ (14,611 ) Net loss per share: Basic and diluted $ (0.26 ) $ (0.26 ) $ (0.48 ) $ (0.45 ) Weighted average number of shares outstanding: basic and diluted 45,970,516 37,254,839 43,745,898 32,574,158 About BB-301 BB-301 is a silence and replace-based genetic medicine currently under development by Benitec. BB-301 uses DNA-directed RNA interference (ddRNAi) to simultaneously silence the mutant gene and replace it with a functional gene, potentially providing a permanent solution with a single administration. This fundamental therapeutic approach to disease management is called “silence and replace.” The silence and replace mechanism offers the potential to restore the normative physiology of diseased cells and tissues and to improve treatment outcomes for patients suffering from the chronic, and potentially fatal, effects of OPMD. BB-301 has been granted Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA. About Benitec Biopharma, Inc. Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at . Forward Looking Statements Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of pre-clinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel AAV vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities and other regulatory developments; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; the impact of, and our ability to remediate, the identified material weakness in our internal controls over financial reporting; the impact of local, regional, and national and international economic conditions and events; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.
RootData: BB will unlock tokens worth approximately $1.13 million in one week
According to token unlock data from the Web3 asset data platform RootData, BounceBit (BB) will unlock approximately 37.03 million tokens, valued at about $1.13 million, at 00:00 on February 13 (GMT+8).
Cipher's AI subsidiary Black Pearl Compute garners $13 billion offers in $2 billion junk bond sale: report
Black Pearl Compute, the AI-focused subsidiary of the bitcoin mining firm Cipher Mining (Nasdaq: CIFR), has attracted massive demand for its $2 billion junk bond sale floated on Tuesday — to the tune of $13 billion of orders, according to Bloomberg. The funding will help finance the construction of the Black Pearl data center in Texas, which was leased to Amazon Web Services for at least 15 years in November. That AWS deal is valued at around $5.5 billion in total contracted revenue for 300 MW of capacity. This outsized interest in Cipher’s debt raise comes as crypto mining firms continue to diversify into the high-performance computing sector and amid pressing demand for AI infrastructure. Mining firms have collectively raised billions of dollars in debt financing to fund site acquisitions, facility retrofitting, and other capital-intensive AI projects. Last year, for instance, Galaxy Digital raised $1.4 billion while TeraWulf sought $3 billion. In September, Cipher signed a 10-year, 168 MW lease with FluidStack that could yield up to $7 billion while proposing a private offering of $1.1 billion in convertible senior notes maturing in 2031. That deal was backed by Google, with the internet giant taking a 5.4% stake in Cipher. FluidStack signed a similar Google-supported deal with TeraWulf. Black Pearl’s new five-year bonds, priced on Wednesday, will yield 6.125%, according to Bloomberg, citing an anonymous source. The funds will also be used to reimburse Cipher approximately $232.5 million for its prior equity contributions to Cipher Black Pearl, among other corporate needs. The senior notes will be secured by first-priority liens on "substantially all assets of the Issuer and the Guarantors" and Black Pearl’s equity interests. Bloomberg noted bonds in the BB junk bond range are yielding an average 5.56%. CIFR shares closed down 12.36% on Wednesday to $14.25 amid a continuing selloff in crypto tokens and equities, according to The Block's data pages. Cipher is the fourth-largest bitcoin mining firm by market capitalization.
Filled orders
Delivery scenarios